Contrasting Beigene (ONC) & Its Rivals

Beigene (NASDAQ:ONC) is one of 1,072 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Beigene to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Volatility and Risk

Beigene has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Beigene’s peers have a beta of 3.64, meaning that their average share price is 264% more volatile than the S&P 500.

Earnings and Valuation

This table compares Beigene and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beigene	$3.81 billion	-$881.71 million	-43.05
Beigene Competitors	$9.93 billion	$136.87 million	-7.22

Beigene’s peers have higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Beigene and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0	0	3	0	3.00
Beigene Competitors	8391	22232	50389	1347	2.54

Beigene currently has a consensus price target of $310.00, suggesting a potential upside of 17.28%. As a group, “Pharmaceutical preparations” companies have a potential upside of 231.44%. Given Beigene’s peers higher possible upside, analysts clearly believe Beigene has less favorable growth aspects than its peers.

Profitability

This table compares Beigene and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
Beigene Competitors	-3,399.87%	-235.11%	-32.77%

Institutional and Insider Ownership

48.5% of Beigene shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 7.4% of Beigene shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Beigene peers beat Beigene on 7 of the 13 factors compared.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.